Author: Colin Macphee

Source: Expert Opinion on Investigational Drugs, Volume 13, Number 9, 1 September 2004 , pp. 1213-1215(3)

Publisher: Informa Healthcare

Abstract:

The conference covered the most exciting recent advances in industry and academia in areas related to drug discovery and development. Topics included candidates currently in clinical development, new technologies aimed at facilitating the drug discovery process and potential new targets. Targets in clinical development included inhibitors of lipoprotein-associated phospholipase A₂ for atherosclerosis, IL-1 converting enzyme inhibitors for inflammatory disorders and a novel proteasome inhibitor for cancer therapy. New technologies covered a novel system for screening ion channel function, various applications for RNA interference, different imaging modalities, as well as mRNA microarrays to facilitate toxicological assessment. New targets included the ATP-binding cassette family of transporters and the recently elucidated sulfation pathways.

Keywords: Alzheimer's disease; atherosclerosis; drug discovery; G-protein coupled receptors; imaging; inflammation; microarrays; myeloma; new targets; RNA interference

Document Type: Meeting report

DOI: http://dx.doi.org/10.1517/13543784.13.9.1213

Publication date: 2004-09-01

More about this publication?

• Editorial Board
• Information for Authors
• Subscribe to this Title
• Terms & Conditions
• ingentaconnect is not responsible for the content or availability of external websites

Related content

• In this: publication
• By this: publisher
• In this Subject: Pharmacology
• By this author: Colin Macphee

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers